ns systems providing unbreakable encryption. It also offers the related and useful capability to squeeze microwave fields, trading reduced noise in the signal phase for increased noise in the signal amplitude. By combining two squeezed entities, scientists can entangle them, linking their properties in predictable ways that are useful in quantum computing and communications. Entanglement of microwave signals, as opposed to optical signals, offer some practical advantages in computing and communication such as relatively simple equipment requirements, Lehnert says.
The new amplifier is a 5-millimeter-long niobium cavity lined with 480 magnetic sensors called SQUIDs (superconducting quantum interference devices). The line of SQUIDs acts like a metamaterial, a structure not found in nature that has strange effects on electromagnetic energy. Microwaves ricochet back and forth inside the cavity like a skateboarder on a ramp. Scientists tune the wave velocity by manipulating the magnetic fields in the SQUIDs and the intensity of the microwaves. An injection of an intense pump tone at a particular frequency, like a skateboarder jumping at particular times to boost speed and height on a ramp, causes the microwave power to oscillate at twice the pump frequency. Only the portion of the signal which is synchronous with the pump is amplified.
'/>"/>
Page: 1 2 Related biology technology :1.
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis2.
GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award3.
Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend4.
Genmab Announces 2007 First Half Year Results5.
Pharsight Achieves First License Sale for Public-Source Database6.
Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments7.
ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials8.
China Medical Technologies Reports First Quarter Financial Results9.
Pressure BioSciences, Inc. Issued First Patent in Canada10.
Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results11.
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer